• Transdiagnostic (TD) treatments have large effects on anxiety and depression.
Introduction
Depressive and anxiety disorders (collectively referred to as emotional disorders) represent one of the largest causes of disability worldwide, with estimated lifetime prevalence rates of up to 29% for anxiety disorders and 19% for depressive disorders (Kessler et al., 2005) . The economic burden is enormous, with depression and anxiety accounting for a third to one half of the global cost of mental illness, currently estimated at $2.5 trillion (2010) , and projected to increase to over $6 trillion by 2030 (WHO Global Burden of Disease: 2004 update, WHO, 2008 . Depressive and anxiety disorders typically develop in late adolescence/early adulthood, and are chronic and relapsing if they remain untreated and even after acute treatment (Judd, 1997) . The burden of these disorders is difficult to overstate: they impair the quality of life of sufferers and their loved ones, reduce workforce participation, contribute to marked occupational impairment and lost productivity (Birnbaum et al., 2010) , and increase risk for the development and morbidity associated with chronic physical conditions (e.g., cardiovascular disease) (Katon, 2011) .
Until relatively recently, the disorder-specific approach has dominated the way in which depressive and anxiety disorders have been conceptualised and researched, and has shaped the way treatments have been developed and evaluated. While this approach to treatment has demonstrable efficacy (Hofmann & Smits, 2008) , there are also significant drawbacks. First, there is substantial discrepancy between the disorder-specific treatment approach with our current understanding of depressive and anxiety disorders. There is strong evidence indicating that similar aetiological and maintenance processes underlie depressive and anxious psychopathology. For instance, anxiety and depressive disorders share many similar genetic, familial, and environmental risk factors (Kendler, 1996; Kessler et al., 2005) , with structural modelling studies showing that a broad internalising liability or a common distress/negative affectivity component underlies anxiety and depressive disorders (Andrews et al., 2009; Watson, 2005) . These disorders also share similar cognitive-affective, interpersonal, and behavioural maintaining factors, with the similarities superseding any minor differences between disorders (Harvey, Watkins, Mansell, & Shafran, 2004) . Second, disorder-specific interventions pay relatively limited attention to comorbidity, despite evidence of high comorbidity rates up to 40-80% in both clinical and epidemiological studies (Brown, Campbell, Lehman, Grisham, & Mancill, 2001; Kessler et al., 2005) . High comorbidity poses a significant problem for both conceptualisation and treatment decisions: how should the treating practitioner provide optimal treatment to a patient presenting with multiple disorders, when the majority of evidence-based treatments (EBTs) are tailored to specific diagnoses?
Third, despite the clinical utility of diagnostic categories, there are also some limitations to the reliability and validity of the diagnostic classifications that disorder-specific treatments have been based on: there is considerable heterogeneity within diagnostic categories, poor discrimination between supposedly distinct emotional disorders, and high rates of not otherwise specified diagnoses (e.g., see Brown, Di Nardo, Lehman, & Campbell, 2001 ). In addition, the ever-growing numbers of treatment manuals for different disorders (and multiple manuals for the same disorder) represent a significant barrier to implementation, dissemination and training, and EBT manuals often share many common elements (e.g., cognitive restructuring) leading to significant redundancy across treatment protocols (Chorpita & Daleiden, 2009) .
Driven by these concerns, there has been growing consensus amongst international experts in the field that a novel approach is needed in the way we classify, formulate, treat, and prevent depression and anxiety disorders (Barlow, Allen, & Choate, 2004) . The move away from the single-diagnosis approach towards a transdiagnostic conceptualisation and treatment of depressive and anxiety disorders represents a significant paradigm shift (Craske, 2012) , mirroring a similar shift in EBTs for eating disorders (Fairburn, Cooper, & Shafran, 2003) . The transdiagnostic approach focuses on identifying the common and core maladaptive temperamental, psychological, cognitive, emotional, interpersonal and behavioural processes that underpin a broad array of diagnostic presentations (Harvey et al., 2004) and targeting these factors in treatment (Barlow et al., 2004) . 'Transdiagnostic or 'unified' treatments apply the same underlying treatment principals across mental disorders, without tailoring the protocol to specific diagnoses ' (p21, McEvoy, Nathan, & Norton, 2009) , and as such operate outside the traditional diagnostic boundaries of DSM (American Psychiatric Association, 2013) or ICD (World Health Organization, 1992) . The transdiagnostic approach is also compatible with the Research Domain Criteria (RDoC), put forth by the U.S. National Institute for Mental Health as an alternative to DSM or ICD, that focuses on the underlying mechanisms (e.g., cognition, negative affect, arousal) that cut across multiple disorders (see Cuthbert, 2014) .
Transdiagnostic psychological treatments have been hailed as a promising new approach to overcome some of the pitfalls of disorder-specific treatments (see Clark & Taylor, 2009; Craske, 2012 for a discussion of the promise and pitfalls of the transdiagnostic approach). In theory, transdiagnostic treatments should enable the treating practitioner to conceptualise the common maintaining processes across presenting issues, and deliver evidence-based treatment strategies within the one protocol, increasing the efficiency and efficacy of treatment, reducing the need for multiple manuals, and increasing the ease of implementation (Chorpita, Taylor, Francis, Moffitt, & Austin, 2004) . At present however, it is unclear whether transdiagnostic treatments meet these high expectations. It remains uncertain how efficacious transdiagnostic treatments are in reducing anxiety and depression symptoms, and in improving quality of life. In addition, although one of the supposed strengths of transdiagnostic treatment approach is that it reduces the need for multiple treatment protocols, an increasing number of transdiagnostic treatments are being developed and evaluated around the world. These protocols differ with respect to the diagnostic combinations and symptom profiles they are designed to target (e.g., multiple anxiety disorders or anxiety and depression), the type of treatment techniques they use (e.g., cognitive behavioural therapy [CBT] versus mindfulness-based treatments), and their delivery format (e.g., group-based versus internet-delivered treatments), but it is unknown whether these differences affect outcomes. In addition, many of the existing evaluations have been conducted with small samples, and therefore may have produced biased estimates of effect sizes, and lacked power to detect potentially important differences between transdiagnostic treatments and control conditions. To address these uncertainties, we conducted a systematic review and meta-analysis to synthesise the evidence from studies evaluating transdiagnostic psychological treatments for adult depressive and anxiety disorders.
Overview of existing transdiagnostic treatments for anxiety and depressive disorders
The transdiagnostic treatments that have been evaluated to-date for anxiety and depressive disorders tend to fall into two broad approaches. The first approach, which has been most researched, is broad-spectrum transdiagnostic CBT (TD-CBT) interventions which target either heterogeneous anxiety disorders (e.g., Norton, 2008) , or anxiety and depression (e.g., McEvoy & Nathan, 2007) . TD-CBT protocols are informed by cognitive and behavioural models of emotional disorders (Barlow, 2000; Beck, 1979; Norton, 2006) and apply a core set of generic CBTbased treatment principles and techniques (e.g., graded exposure and cognitive restructuring) to target the common processes underlying anxiety and depression, rather than targeting the symptoms of specific disorders. In contrast to this traditional CBT-based transdiagnostic approach, there has also been increasing interest in "third wave" or "new wave" behavioural and cognitive behavioural therapies such as acceptance-and mindfulness-based interventions for the transdiagnostic treatment of anxiety and depressive disorders (for a review of terminology see Hofmann, Sawyer, Witt, & Oh, 2010) . Unlike traditional CBT, which aims to modify dysfunctional cognitions, behaviours and emotions, acceptance-and mindfulness-based interventions aim to change a person's perspective on, and relationship with their cognitions and emotions. This process is facilitated through mindfulness, non-judgemental awareness, and acceptance of psychological experiences. Norton, 2008 ), individual (Arch et al., 2012 , computerised (anxiety and depression: Proudfoot et al., 2004) and online delivery formats (mixed anxiety disorders: Johnston, Titov, Andrews, Spence, & Dear, 2011; anxiety and depression: Titov et al., 2011) . While it is still unclear which delivery format leads to superior outcomes, these studies have found moderate to large uncontrolled effect sizes (ESs) for reductions in anxiety symptoms (e.g., d = 1.68), depression and functional impairment (e.g., Norton, 2008) . In randomised controlled trials (RCTs) TD-CBT has been shown to be more effective compared to waitlist control (WLC) in group-format (controlled between-group ES: d = .50) (Erickson, Janeck, & Tallman, 2007) and online delivery . However, there have been few RCTs comparing TD-CBT with attention control conditions or other psychological treatments, and those conducted give a more modest account of the impact of TD-CBT. For example, although Norton (2012) found lower drop-out rates during group TD-CBT, there were no significant differences in anxiety severity at post-treatment compared to relaxation training.
In addition, there is also discrepancy in the literature of existing RCTs regarding how effective TD-CBT treatments are compared to disorderspecific CBT treatments. For example, in one RCT, Craske et al. (2007) showed that a disorder-specific programme of group plus individual CBT sessions that was targeted solely at a patient's primary panic disorder was more effective than a CBT protocol that targeted both the primary panic disorder and comorbid disorders (e.g., depression). In contrast, in another RCT, Norton and Barrera (2012) found no significant differences between group-based TD-CBT and disorder-specific group CBT for anxiety disorders. The latter study was likely to be underpowered to detect statistically significant differences between the two treatment approaches. Our aim was to use meta-analytic techniques to combine the results across multiple RCTs comparing transdiagnostic to disorder-specific treatments. By combining the results of individual trials, meta-analysis has the potential to increase the power to detect differences across these treatment approaches.
In addition to broad-spectrum TD-CBT, other variations to TD-CBT have been developed and evaluated. For example, Barlow and colleagues' Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) (Ellard, Fairholme, Boisseau, Farchione, & Barlow, 2010 ) is a transdiagnostic emotion-focused CBT-based intervention which aims to improve emotional awareness and emotion regulation skills, facilitate cognitive and emotional flexibility, and reduce avoidance and maladaptive emotion-driven behaviours. The UP has been demonstrated to lead to robust effects on anxiety and depression symptoms in two uncontrolled trials Wilamowska et al., 2010) , and is more effective than a wait list control (WLC) in reducing anxiety (controlled between-group ESs: 0.56 on the BAI, and 1.39 on the clinician severity ratings of (co) principal diagnosis), and depression (controlled betweengroup ESs: 1.11 on the BDI-II) (Farchione et al., 2012) . Another variation of TD-CBT is group-based false safety behaviour elimination therapy (F-SET), which focuses solely on the reduction of transdiagnostic safety seeking behaviours and safety signals. F-SET has been shown to have large effects in the reduction of both self-reported and clinician-rated anxiety severity (uncontrolled pre-to post-treatment ESs: d = 0.8-1.1), moderate effects for depression (uncontrolled ES: d = .73), and medium to large between group effect sizes compared to WLC on anxiety outcomes at post-treatment (controlled between-group ES: d = .77), with gains maintained up to 6 months (Schmidt et al., 2012) .
Transdiagnostic mindfulness-and acceptance-based treatments
While there have been fewer evaluations of transdiagnostic mindfulness-and acceptance-based treatments, results suggest that they provide a viable and effective treatment option for emotional disorders. For example, Kabat-Zinn and colleagues (Kabat-Zinn et al., 1992; Miller, Fletcher, & Kabat-Zinn, 1995) , and more recently, Arch and colleagues (Arch et al., 2013) have evaluated the impact of mindfulnessbased stress reduction (MBSR) with mixed samples of participants with emotional disorders. MBSR is a group-based treatment that combines psychoeducation with yoga and intensive guided mindfulness-based meditation practices (e.g., body scan, formal sitting meditation). KabatZinn et al. (1992) demonstrated large uncontrolled ESs (0.88 on the BAI) for reduction in anxiety symptoms following MBSR, that were maintained three years post-treatment (Miller et al., 1995) . More recently, Arch et al. (2013) compared MBSR with TD-CBT in an RCT, and found that both MBSR and TD-CBT led to large reductions in the severity of primary anxiety diagnoses, worry, anxious arousal and depression symptoms. Although there were no significant overall differences between MBSR and TD-CBT, there were small effect sizes in favour of MBSR for the severity of primary diagnoses and worry frequency at follow-up (controlled between-group ES: d = .29) and in favour of TD-CBT (controlled between-group ES: d = .31) for reducing anxious arousal. These results indicate that MBSR provides an efficacious treatment option for people with multiple emotional disorders ( Arch et al., 2013) , and may have comparable effects to TD-CBT.
In another recent RCT, Arch et al. (Arch et al., 2012) compared the efficacy of individual TD-CBT to individual acceptance and commitment therapy (ACT). ACT (Hayes, Strosahl, & Wilson, 1999 ) is a psychological therapy that combines psychoeducation and experiential exercises that encourage mental flexibility, cognitive defusion, mindfulness and acceptance of experiences and the reduction of experiential avoidance. ACT interventions also aim to reduce experiential avoidance by promoting active engagement in activities and behaviours that are done in pursuit of ones goals and personal values. The authors did not find any significant differences between individual TD-CBT compared to ACT at post-treatment, likely due to lack of power. However, there was a small to medium effect in favour of TD-CBT for improvements in quality of life (d = .42), and a large effect for lower primary disorder severity ratings at 12 months post-treatment for the ACT group (d = 1.10, for the completer sample only) that did not reach significance. Unfortunately, there were too few participants to detect whether CBT conferred significant benefit over ACT or vice versa. Our aim was to combine the results across individual trials using meta-analysis to shed light on whether the type of transdiagnostic treatment influences outcomes.
1.4. Previous systematic reviews and meta-analyses of transdiagnostic psychological treatments and gaps in the existing literature To date, there have been no previous attempts to systematically review the full set of transdiagnostic psychological treatments for anxiety and depressive disorders, beyond CBT delivered face-to-face. There has been one narrative review of transdiagnostic treatments for depression and anxiety disorders (McEvoy et al., 2009) , and two meta-analyses of transdiagnostic interventions, both restricting their focus to face-toface CBT protocols for anxiety disorders (Norton & Philipp, 2008; Reinholt & Krogh, 2014) . The first meta-analytic review published by Norton and Philipp (2008) found large mean uncontrolled effect sizes for pre-to post-treatment reductions in anxiety (d = 1.29, 95%CI: 0.66-1.93). However, they only examined the uncontrolled effect sizes because of the lack of available evaluations that included comparison control conditions at the time of review. In a more recent evaluation, Reinholt and Krogh (2014) carried out a meta-analysis of 11 RCTs of TD-CBT protocols for anxiety disorders that had been published prior to June 2013, and found that TD-CBT outperformed WLC and treatment-as-usual (TAU) control conditions, with a medium overall difference between groups in anxiety severity at post-treatment (d = .68, . The results suggested that RCTs using WLC conditions had larger effect sizes (controlled ES: d = 1.00) compared to those that used TAU control conditions (controlled ES: d = .28).
Together these meta-analyses provide promising evidence for the efficacy of TD-CBT protocols in reducing anxiety severity, but there are questions that await further investigation. Because Reinholt and Krogh (2014) included anxiety severity as their sole outcome measure, it remains unclear whether transdiagnostic treatments have differential effects on anxiety compared to depression, and what impact they have on quality of life. Measurement of quality of life is particularly important because quality of life is a standard measure used not only for the calculation of QALYs (quality-adjusted-life-years), but in health economic analyses (e.g., cost utility analyses). The degree to which gains are maintained following transdiagnostic treatments also awaits further evaluation. In addition, both of the meta-analyses restricted their analysis to CBT interventions that were delivered face-to-face. A more inclusive systematic review and meta-analysis is now needed that comprehensively reviews: (i) the full set of transdiagnostic treatments for emotional disorders, including CBT as well as "third wave" ACT and mindfulness-based interventions, and (ii) treatments that are delivered across different formats, including face-to-face group, individual, and computerised treatments. Understanding whether the type of transdiagnostic treatment and the delivery format have an impact on outcomes has the potential to inform both clinical practice and future treatment developments in this area. In addition, Reinholt and Krogh (2014) only explored how transdiagnostic treatments compare to WLC and TAU control conditions. Further research is therefore needed to explore how transdiagnostic treatments perform on average relative to no-treatment/WLC controls versus TAU, as well as against other attention control conditions (such as relaxation training or psychological placebo), and disorder-specific treatments.
Aim/objectives
The aim of this review was to provide a comprehensive review of the published studies evaluating transdiagnostic psychological treatments for adults with depression and/or anxiety disorders. In conducting this review, we aimed to answer three main questions: (1) what are the overall effects of transdiagnostic treatments on depression, anxiety and quality of life?; (2) what is the relative efficacy of transdiagnostic treatments versus various control conditions (WLC, TAU, attention control and disorder-specific treatments)?; and (3) what is the impact of potential moderators of treatment effect including type of treatment and delivery format?. The final aim of this review was to provide recommendations for future research and treatment development.
Methods

Protocol and registration
We followed the PRISMA guidelines for reporting of this systematic review (Moher, Liberati, Tetzlaff, Altman, & The, 2009 ). This review protocol was developed following the procedures outlined in the Cochrane Handbook for systematic reviews (Higgins & Green, 2011) , and the protocol was registered with PROSPERO 2 [CRD42014010469].
Inclusion/eligibility criteria
(i) Types of participants: We included studies in which participants were adults (18 years and older), who met DSM or ICD criteria for a primary diagnosis of an anxiety or depressive disorder or mixed anxiety and depression, established by a formal validated diagnostic interview. Because the search protocol was initially developed with DSM-IV-TR diagnostic categories in mind (American Psychiatric Association, 2000), we included posttraumatic stress disorder (PTSD) and acute stress disorder (ASD) as anxiety disorders, although they are now classified as trauma and stressorrelated disorders in DSM-5 (American Psychiatric Association, 2013). Depressive disorders included major depressive disorder (MDD), dysthymic disorder, and minor depression. For the purposes of determining whether studies met our inclusion criteria, depressive disorders were classified as one disorder category (e.g., dysthymic disorder and major depression were grouped together under the category of 'depressive disorder/depression'). (ii) Types of interventions: We included studies of manualised psychological treatments for adults that lasted for 2 or more sessions and targeted: (i) two or more anxiety disorders; (ii) at least one anxiety disorder together with a depressive disorder/depression. Face-to-face clinician-delivered treatments were included. Internet-or computer-delivered treatments were included only if they were clinician-guided. Clinician-guided internetor computer-delivered treatments were defined as treatments that involved having some form of email and/or telephone contact with a therapist, clinician or support person during the treatment or intervention period; that is, the clinician contact was not just restricted to pre-treatment assessment interviews. (iii) Types of comparisons and outcomes: Studies were included that reported at least one validated self-report measure of anxiety or depression at both baseline and post-treatment, enabling us to calculate at minimum, the average uncontrolled effect size on primary outcome measures. Given we were interested in examining the maintenance of gains following treatment; we were also interested in examining outcomes at short-term follow-up (defined as up to 6 months post-treatment). We also included randomised trials in which the effects of transdiagnostic treatment were compared with either: (a) a no-treatment (WLC) condition; (b) a care-as-usual, or treatment-as-usual control condition (TAU); (c) another control psychological treatment (e.g., relaxation) or attention control condition; or (d) a disorder-specific psychological treatment. This enabled us to calculate between-groups effect sizes based on comparisons between conditions at post-treatment. Diagnostic status was not used as an outcome variable because there were too few studies that reported this variable at posttreatment or follow-up. (iv) Types of study design: We included studies published in English in a peer-reviewed journal up to February 28, 2014. We included all uncontrolled (open) trials which involved a prepost-study design, or randomised controlled trials comparing transdiagnostic interventions to a control condition. RCTs with multiple control conditions were also included as long as all of the other inclusion criteria were met. One of the purposes of this study was to conduct a comprehensive overview and examination of the available literature. Therefore, we chose to include uncontrolled trials as well as RCTs, rather than restricting our analysis to the available RCTs.
Excluded studies
We excluded studies in which the psychological treatment was not manualised, studies in which there was insufficient data reported to calculate effect sizes and where we could not obtain those data, and studies that focused on populations under age 18. Case studies and case series were also excluded. Finally, studies with mixed samples with psychotic disorders, personality disorders, and substance use disorders were excluded. Treatment protocols that involved combinations of pharmacological and psychological interventions were excluded. Entirely selfguided computerised or internet-delivered treatments were also excluded.
Identification and selection of studies
To identify studies for possible inclusion, we conducted comprehensive systematic searches of the electronic databases PSYCInfo, and PubMed up to 28 February 2014 (see Appendix A for our electronic search strategy for PSYCInfo). To broaden the search criteria and maximise the sensitivity of our search, we combined terms indicative of anxiety, depression, mixed anxiety and depression, anxious depression, as well as various anxiety and depressive disorders with the terms 'transdiagnostic' and a large range of psychotherapies such as various forms of CBT, stress management, mindfulness-based therapies (e.g., MBSR), ACT, attention training, metacognitive therapy (MCT) and psychotherapy. We searched for a range of study types including uncontrolled open trials, effectiveness studies and randomised trials. We also searched the references lists of relevant manuscripts and previous reviews of this literature, to identify additional studies that met our inclusion criteria.
Study selection
The first author (JN) initially screened all of the titles and abstracts for all studies to determine their relevance to this study. Studies that could be immediately excluded on the basis of the title and abstract were discarded. For the remaining references, full text manuscripts were reviewed for more comprehensive evaluation of the study inclusion criteria. Both JN and AM independently read each full text to assess eligibility for inclusion, and disagreements were resolved through discussion, and consultation with TD.
Data extraction and management
Data regarding methodology and outcome measures were extracted into a Microsoft Excel spread sheet by JN (which was independently checked by a research assistant), before being transferred to Comprehensive Meta-Analysis (version 2.0; Biostat, Inc.) for the metaanalysis. The following information from each study was extracted: authors, year of publication, setting, diagnostic assessment measure, mean age, gender (proportion female), type of intervention (e.g., CBT, ACT), delivery format (face-to-face individual, internet/computer, and faceto-face group), duration of intervention, and attrition rates. Outcome data for the primary and secondary outcome measures assessing anxiety, depression, and quality of life were also extracted. For multiple reports of the same study, we combined the outcome measures and considered them as one study.
Primary outcomes
1. Symptoms of anxiety, according to continuous symptom measures such as the Beck Anxiety Inventory (BAI) , Generalised Anxiety Disorder 7-item scale (GAD-7) (Spitzer, Kroenke, Williams, & Lowe, 2006) , or the Anxiety subscale of the Depression Anxiety Stress Scale (DASS-21) anxiety subscale (Lovibond & Lovibond, 1995 Beck, Steer, & Brown, 1996) , the nine-item Patient Health Questionnaire (PHQ-9: Kroenke, Spitzer, & Williams, 2001) or the Depression subscale of the DASS-21 (Lovibond & Lovibond, 1995) . 3. Quality of life according to general measures of quality of life or functional impairment including the Euro-Qol (Euroqol Group, 1990) or the SF-12 (Ware, Kosinski, & Keller, 1996) .
We extracted and analysed outcome data on self-reported symptoms of depression, anxiety and quality of life at post-treatment and follow-up. There was not enough information reported in the studies to analyse diagnostic status following treatment. Because many of the studies used more than one instrument to measure anxiety (or depression) we used the primary outcome as reported by the study investigators, or if absent, we used the most frequently used measures across studies (BAI, GAD-7, and BDI, PHQ-9, DASS-21 depression subscale). All included studies reported means and standard deviations at postintervention, allowing us to calculate the effect size directly, but there were only 24 studies that reported at least one outcome measure at 3-to 6-months follow-up.
Risk of bias in individual studies
We assessed the quality and risk of bias of included RCTs using the 'Risk of Bias' tool, developed by the Cochrane Collaboration (Higgins & Green, 2011) . This tool allowed us to assess possible sources of risk in RCTs, including: (1) allocation sequence (the method used to generate the allocation sequence is provided in sufficient detail to allow an assessment of whether it should produce comparable groups), (2) allocation concealment (the method used to conceal the allocation sequence is given in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment), (3) blinding of participants, personnel and outcome assessors (all measures used to blind outcome assessors from knowledge of which intervention a participant received), (4) incomplete outcome data (assessment of the completeness of outcome data from each main outcome including attrition and exclusions, and whether all randomised participants were included in the analyses). The assessment of study quality was conducted by two independent reviewers (JN and AM) and disagreements were resolved via discussion. See Table 1 for quality ratings of included controlled trials.
3.9. Statistical analyses 3.9.1. Calculation of effect sizes: changes on primary outcome measures between pre-and post-treatment, and pre-treatment and follow-up
To examine the within-group effect (uncontrolled effect size) of transdiagnostic psychological treatments, for each treatment we calculated the effect size referring to the difference between baseline and post-treatment (or between baseline and follow-up), divided by pooled standard deviation on each primary outcome measure, and the 95% confidence intervals around the effect sizes. Effect sizes were also adjusted to address small sample sizes, according to the procedures outlined in Hedges and Olin (1985, or Hedges g) . Because the baseline and posttreatment values are not independent from each other, the correlation between time points was required, but most studies did not include the correlation within the body of the manuscript. In the absence of the correlation between time-points, we used a conservative value of 0.50 (Balk, Earley, Patel, Trikalinos, & Dahabreh, 2012) . 
Calculation of effect sizes: transdiagnostic treatments versus controls
For each comparison between a transdiagnostic psychological treatment and a control condition, we calculated the effect size (Hedges g) referring to the difference between the two groups at post-treatment (standardised mean difference) and the 95% confidence intervals around the effect sizes. Effect sizes were calculated by subtracting the average score of the transdiagnostic treatment at post-treatment from the average score for the control group, and dividing the result by the pooled standard deviation of the two groups. Effect sizes of 0.2, 0.5 and 0.8 refer to small, moderate and large effect sizes respectively (Cohen, 1988) . Effect sizes were also adjusted to address small sample sizes, according to the procedures outlined in Hedges and Olin (1985, or Hedges g).
To calculate pooled mean effect sizes, we used the programme Comprehensive Meta-Analysis (version 2.0, Biostat Inc.). Given that Reinholt and Krogh (2014) found evidence of heterogeneity, we similarly expected substantial heterogeneity amongst the interventions, and therefore calculated the mean effect sizes using a random effects model. The random effects model assumes that the true effect size varies from one study to the next, and that the studies in our analysis represent a random sample of effect sizes that could have been observed. The summary effect is our estimate of the mean of these effects (Borenstein, Hedges, Higgins, & Rothstein, 2009 ).
Subgroup analyses
To assess the differences between subgroups (treatment type: CBT vs. mindfulness/acceptance-based treatments; treatment format: individual, group and computer/internet interventions), and the differences in outcomes on anxiety versus depression measures, we conducted subgroup analyses using the mixed effect model approach with the dataset that included all studies with pre-to post-treatment data. In this model, a random-effects model is used to pool studies within subgroups (e.g., individual treatment), and we test for significant differences between subgroups using a fixed-effects model.
Testing homogeneity
To test the homogeneity of effect sizes, we calculated the I 2 statistic, which is an indicator of heterogeneity across effect sizes, and is provided as a score in percentages. A value of 0% indicates no heterogeneity, whereas scores of 25%, 50% and 75% indicate low, moderate, and high heterogeneity, respectively.
3.12. Risk of bias across studies 3.12.1. Testing for publication bias and dealing with publication bias To test for publication bias, we inspected the funnel plot on the primary outcome measures (for depression, anxiety and quality of life measures respectively) (Egger, Davey Smith, Schneider, & Minder, 1997) . In addition, we also conducted Duval and Tweedie's Trim and Fill procedure (Duval & Tweedie, 2000a , 2000b within Comprehensive Meta-Analysis, which yields an adjusted effect size that takes into account the publication bias observed within the funnel plot. This procedure corrects for the variance of the effects and provides a best estimate of the unbiased effect size. Fig. 1 presents the flowchart describing the inclusion of studies. A total of 10958 titles and abstracts were examined. 10589 were rejected at title and abstract, and a further 323 were rejected after the entire article was reviewed. This left a total of 47 studies (from 46 articles) that were analysed. Of these, 31 were RCTs, 15 were uncontrolled trials, and one was a non-randomised trial.
Results
Study selection
Study characteristics
Characteristics of the included studies are found in Table 1 . Because some studies reported evaluations of either separate groups undergoing the same treatment (e.g., results for immediate and delayed treatment undergoing internet-delivered CBT [iCBT], Titov, Andrews, Johnston, Robinson, & Spence, 2010) , or different transdiagnostic treatments (e.g., results for ACT and CBT, see Arch et al., 2012), we were able to include 50 studies in which 1865 patients participated to calculate the average uncontrolled effects of transdiagnostic treatments between pre-and post-treatment. The majority of these examined TD-CBT or variants of TD-CBT such as behavioural activation combined with exposure therapy, and anxiety management with virtual reality exposure (n = 40). Seven studied mindfulness/acceptance-based interventions (of which one was ACT) and three evaluated other forms of psychotherapy (e.g., short term psychodynamic psychotherapy). Five studies evaluated TD-CBT in older adult samples only (N55 years, mean age = 69 years), and the remainder included working age adults over 18 years of age (mean age = 39 years). The samples were predominantly comprised of females (mean proportion of females = 63%). With regard to treatment format, 17 evaluated computer/internet, 18 face-toface group, and 17 face-to-face individual treatment format. In most studies of face-to-face therapies, the treatments had 12 or fewer treatment sessions (range 6-40 sessions). Rates of attrition varied across studies from 0% to 56% (see Table 1 ).
Of the 31 RCTs, there were 27 studies (reporting 29 comparisons) included in the meta-analysis comparing transdiagnostic treatments (n = 1109) to control conditions (n = 992). The studies ranged in sample size from 10 to 121 per condition. For the control conditions, 12 used WLC condition, 4 used treatment-as-usual (TAU) or (enhanced) usual care control conditions, two used discussion forums, one online clinical support, two used relaxation training, one supportive counselling, three used psychoeducation as a control condition, and four used disorderspecific treatments. In addition, there were two studies (with 233 participants altogether) which compared two alternative types of transdiagnostic interventions (TD-CBT versus ACT, group MBSR versus group TD-CBT). There was also one randomised comparison between computerised versus face-to-face TD-CBT, and another study that used antidepressant medications and pill placebo as their control condition. 
Pre-treatment diagnostic assessment and outcome measures
The majority of the studies administered the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First, Spitzer, Gibbons, & Williams, 1996) , the Anxiety Disorders Interview Schedule (ADIS-IV) (Brown, Dinardo, & Barlow, 1994) or the Mini International Neuropsychiatric Interview version 5.0.0 (MINI) (Sheehan et al., 1998) to obtain a diagnostic assessment at pre-treatment. A wide range of outcome measures were used to assess self-reported anxiety and depressive symptoms and quality of life, with the most common the BAI, the BDI (or BDI-II), and the QOLI. Only 39 out of 50 studies that reported pre-to post-treatment effects incorporated quality of life assessment measures.
Risk of bias within randomised controlled trials
The methodological quality of the studies reporting RCTs varied widely (see Table 1 ). Twenty one (68%) reported adequate generation of random sequencing, 14 (45%) reported adequately concealing group allocation, and 21 (68%) reported appropriate blinding of outcome assessments. Twenty four (78%) studies were coded as at low risk of bias for incomplete outcome data, and 30 studies (97%) were found to have low risk of bias for selective reporting of outcomes. Overall, only seven studies were classified by reviewers as at low risk of bias on all five measures of risk of bias. Thirteen studies were low risk on four, 5 on three, 4 on two, and 2 were low risk of bias on either none or only one measure. 
ADIS-IV ADIS CSR, CGI, ADDQ, BAI, PDSS, SPDQ, GAD-Q-IV, STAI-S
RCT:TD-GCBT: 30% RT: 57% Note. Countries: USA = United States of America, UK = United Kingdom. Treatments: ACT = acceptance and commitment therapy, CBT = cognitive behaviour therapy, CG-ERP = clinician guided exposure and response prevention, DS = disorderspecific, E-COM = enhanced community treatment, F-SET = false safety behaviour elimination therapy, GCBT = group cognitive behaviour therapy, GMBSR = group mindfulness based stress reduction, iCBT = internet-delivered cognitive behavioural therapy, iCBT (CO) = internet cognitive behavioural therapy with coach guidance, iCBT ( The analysis of studies that reported pre-to post-treatment effects showed a mean effect size (Hedges g) of 0.86 for anxiety (n = 50) (95%CI: .75-.96, p b .001), 0.91 for depression (n = 41) (95%CI: .78-1.04, p b .001), and .69 for quality of life (QOL) (n = 29) (95%CI: .59-.78, p b .001). Hedges g values for transdiagnostic treatments, at post-treatment on anxiety and depression are presented in Figs. 2 and 3 respectively (and see Fig. 4 for QOL outcomes). Heterogeneity was moderate to high, and significant amongst these studies (anxiety: I 2 = 72, depression: I 2 = 78, QOL: I 2 = 43). Heterogeneity remained significant even after removal of studies investigating older samples, after removal of studies with high proportion of male participants, and after removal of potential outliers (ps b .001).
4.6. Subgroup analyses of uncontrolled pre-to post-treatment effects 4.6.1. Is there a differential effect of transdiagnostic interventions on depression versus anxiety symptoms between pre-and post-treatment?
For the first subgroup analysis, we selected only the studies that reported both depression and anxiety (n = 39) outcomes to evaluate the magnitude of the uncontrolled (before and after treatment) effects for depression and anxiety symptoms when both are targeted as outcomes and to compare these effects. Transdiagnostic interventions had large effects on both anxiety (g = .85) and depression (g = .92), but overall had a larger effect on depression symptoms compared to anxiety symptoms (Q = 3.94, df = 1, p = .047). 
What is the impact of treatment delivery format on pre-to-posttreatment outcomes?
In the next subgroup analyses (see Table 2 ), we compared the mean uncontrolled effect for subgroups based on treatment delivery format (individual, group and computer/internet interventions), and found significant differences for anxiety symptoms (Q = 31.75, df = 2, p b .001). While we were unable to compare between specific formats, observation of the means suggests that group-based treatments yielded lower effects (n = 18: g = .70) than individual (n = 15: g = .97) and computer/internet treatments (n = 17: g = .96).
5 There were also significant group differences in the size of the uncontrolled effects for depression symptoms (Q = 12.41, df = 2, p = .002), with observation of the means indicating that the highest effect sizes were found in computerised/internet treatments (n = 16: g = .96), followed by group-based face-to-face treatments (n = 12: g = .89) and individual treatments (n = 13: g = .86). However, there were no significant differences between studies which used computer, group, or individual treatment for quality of life measures (individual, n = 10: g = .68, computer/internet, n = 15: g = .74, group, n = 4: g = .65, Q = 3.5, df = 2, p = .17).
What is the impact of treatment type on pre-to-post-treatment outcomes?
In the next subgroup analysis (see Table 2 ), we compared the mean uncontrolled effect for subgroups based on treatment type (CBT versus mindfulness/acceptance based interventions), and showed that there was a significant difference favouring CBT compared with mindfulness/ acceptance based interventions for reducing anxiety symptoms (Q = 7.95, df = 1, p = .005) (CBT, n = 40: g = .88, mindfulness/acceptance, n = 7: g = .61). This difference remained significant even after removing an outlier (Arch et al., 2013) . There were no significant differences across treatment type for depression symptoms (Q = .78, df = 1, p = .38), although observation of the uncontrolled effect estimate suggests that it was slightly higher (albeit not significant) in the mindfulness/acceptance interventions (mindfulness/acceptance, n = 6: g = .92, CBT, n = 31: g = .84). Quality of life was not assessed because only one mindfulness/ acceptance study included an appropriate measure.
Effects of transdiagnostic psychological treatments on primary outcomes between pre-treatment and follow-up (uncontrolled effect sizes)
There were 24 studies that reported follow-up data (15 reporting 3-month follow-up and 9 studies reported 6-month follow-up data). Pre-treatment to follow-up uncontrolled effects were large on average for anxiety (g = 0.87, n = 24, 95%CI: .73-1.01, p b .001), depression 
Between-group effects of transdiagnostic psychological interventions versus control groups
We compared the effects of transdiagnostic treatments with control groups in 24 studies (see Figs. 5, 6 , and 7 for forest plots of anxiety, depression, and quality of life outcomes respectively). These analyses excluded studies that compared transdiagnostic treatments with alternative transdiagnostic interventions, with disorder-specific interventions, and comparisons between alternative versions of the same programme. The overall effect was medium for anxiety severity (n = 24, g = .65, 95%CI: .51-.79), with moderate and significant heterogeneity (I 2 = 51), large for depression (n = 22, g = .80, 95%CI: .62-.98), with moderate heterogeneity (I 2 = 66), and medium for quality of life measures (n = 13, g = .46, 95%CI: .34-.57).
4.8.1. Subgroup analyses: does the magnitude of effect depend on the type of control condition? Next, we conducted a subgroup analysis to explore whether the magnitude of between-group controlled effect differs according to the type of control condition (WLC: n = 13, TAU: n = 4, attention control: n = 8) and found that there was a significant overall effect of control condition on anxiety outcomes (Q = 19.56, df = 2, p b .001).
Comparisons between transdiagnostic treatments versus TAU control conditions had the smallest differences (g = .24, 95%CI: .05-.43, p b .01), whereas there were large differences in comparisons between transdiagnostic treatments and attention control conditions (g = .80, 95%CI: .52-1.08, p b .001) and WLC conditions (g = .70, 95%CI: .56-.84, p b .001).
For depression, there was also a significant difference in the magnitude of effect depending on the type of control condition (Q = 7.08, df = 2, p = .029), with comparisons with TAU control conditions again showing the smallest difference (g = .57, n = 4, 95%CI: .38-.76, p b .001), followed by attention controls (g = .69, n = 8, 95%CI: .46-.91, p b .001) and WLC having the largest difference compared to transdiagnostic treatments (g = 1.0, n = 12, 95%CI: .69-1.30, p b .001). The results of quality of life measures did not reach conventional significance (Q = 1.40, df = 2, p = .49) (WLC: n = 7, g = .53, 95%CI: .34-.71, p b .001, TAU: n = 2, g = .37, 95%CI: .16-.58, p b .001, and attention control conditions: n = 4, g = .42, 95%CI: .16-.68, p b .001), however there were only two comparisons with TAU control conditions.
Risk of bias across studies
There was some evidence of publication bias as demonstrated by inspection of the funnel plot (see Appendix C), and using Duval and Tweedie's Trim and Fill procedure. After adjusting for publication bias using the Trim and Fill procedure, the estimate of the mean effect size comparing transdiagnostic interventions to controls on anxiety reduced from g = .66 to g = .46 (n = 9 studies removed). There was no evidence of publication bias for depression outcomes, nor for quality of life.
Comparisons between transdiagnostic treatments versus disorderspecific treatments
Only four studies compared transdiagnostic interventions to disorder-specific treatment control conditions. The analysis showed that there were no significant differences between transdiagnostic and disorder-specific treatments for anxiety (n = 4, g = .15, 95%CI: − .09-.38, p = .22, I 2 = 0, p N .05), but there were significant differences for depression outcomes, with the results in favour of the transdiagnostic treatments (n = 3, g = .58, 95%CI: .003-1.16, p = 0.05). Notably, there was high heterogeneity (I 2 = 76, p b .05) amongst these effects.
Discussion
In the current study, we systematically reviewed the existing literature on transdiagnostic psychological treatments for depression and anxiety disorders in adults. We examined their overall effect on symptoms of depression, anxiety, and quality of life, as well as the relative efficacy of transdiagnostic treatments compared to waitlist controls (WLC), treatment-as-usual conditions (TAU), attention control conditions and disorder-specific treatments. We identified 47 studies (including 31 RCTs) with a total of 3705 participants evaluating transdiagnostic treatments. The majority of included studies investigated CBT protocols or variants of CBT, and a variety of treatment delivery formats were evaluated, with face-to-face group treatment the most commonly studied.
Analysis of the results across all studies that reported baseline and post-treatment data showed that transdiagnostic treatments lead to large and significant reductions in both anxiety and depression, and Note. CBT = cognitive behavioural therapy; CI = confidence interval; N = number of studies; QOL = quality of life.
moderate improvements in quality of life. Results at short-term follow-up (three to six months after treatment) also suggest that these positive outcomes are maintained following treatment. However, the evidence of high heterogeneity suggests that there were significant differences in treatment effects across studies. Importantly transdiagnostic treatments seem to have a large effect on both depression and anxiety symptoms in studies that targeted both outcomes, providing important support for their transdiagnostic utility. There was also some preliminary evidence that in studies that measured both outcomes, the effects were larger for depression than anxiety. Because the majority of studies only examined general measures of anxiety, the impact on specific mechanisms and outcomes that characterise different fears (e.g., fears of social situations, or fears of physical sensations) still remains unclear. Nevertheless, these positive effects of transdiagnostic treatments are consistent with the findings of previous meta-analyses (Norton & Philipp, 2008 ) and a narrative review (McEvoy et al., 2009) . Notably, our effect estimates for anxiety were lower than a previous meta-analysis of TD-CBT (Norton & Philipp, 2008 who found d = 1.29). This may be because we evaluated a wider range of treatment protocols, or because of methodological differences between studies. For example, we only included studies which employed more rigorous inclusion criteria (e.g., used structured diagnostic interviews). We also used Hedges g rather than Cohen's d, which provides a more conservative estimate of effect sizes by adjusting for small sample sizes. The majority of trials compared transdiagnostic treatments to WLC, but transdiagnostic treatments were also compared to a range of attention control conditions that included psychoeducation, online discussion forums, and supportive counselling. There was only one direct comparison with medication, highlighting the need for future RCTs to compare the efficacy of transdiagnostic psychological treatments to pharmacological interventions for depression and anxiety. Analysis of the pooled results from the RCTs demonstrated that transdiagnostic treatments outperformed controls on all three outcome measures. Similar to Reinholt and Krogh (2014) , we found moderate differences between transdiagnostic treatments and control conditions in anxiety severity at post-treatment. We also demonstrated large overall differences between transdiagnostic treatments and control condition in depression severity, and moderate differences in quality of life at posttreatment. This is the first meta-analysis to demonstrate the positive impact of transdiagnostic treatments on improving quality of life. Compared to the effects found in a recent meta-analysis of CBT for anxiety disorders on quality of life outcomes, our uncontrolled effects were slightly higher (g = .69, versus g = .54 in Hofmann, Wu, & Boettcher, 2014) , but the controlled effects were slightly lower (g = .46 versus g = .56 averaged across group, individual and internet treatments in Hofmann et al., 2014) . Heterogeneity was also moderate to high for all outcome measures, suggesting there was significant variability amongst these effects. We also found some evidence of publication bias for anxiety outcomes, which suggests these effect estimates may be inflated. In addition, the quality assessments revealed that 24 out of 31 RCTs were at high risk of finding biased estimates of effects, based on commonly used risk of bias indices (Higgins & Green, 2011) .
Our preliminary results suggest that the nature of the control condition influenced the size of treatment effects in this study, which may in part explain some of the heterogeneity we observed. We found large differences between transdiagnostic treatments compared to both WLC and attention control conditions (e.g., psychoeducation, online discussion forums, relaxation training). In contrast, we found only small overall differences in studies that compared transdiagnostic treatments to TAU or 'usual care' control conditions in anxiety outcomes, which supports the findings of Reinholt and Krogh (2014) . These results demonstrate that transdiagnostic treatments have benefits over and above the natural recovery processes that often occur across time during the course of depression and anxiety problems (e.g., spontaneous recovery), as well as the non-specific or 'common' therapeutic factors associated with treatment that may account for symptom improvement (e.g., therapeutic alliance, regular assessment and monitoring).
It is unclear why there was a smaller difference between transdiagnostic treatments compared to usual care, whereas transdiagnostic treatments outperformed other control conditions to a larger degree. It is possible that the use of TAU control conditions was confounded with the type of treatment, the duration of the treatment period being evaluated, the quality of the study, or the country where the study was conducted. Three of the four studies were coded as having low risk of bias on all measures. Two of the four studies that used TAU control conditions evaluated alternative forms of psychotherapy (other than CBT) such as problem-solving therapy and short-term psychodynamic psychotherapy in China and Italy, respectively. The remaining two studies compared computerised CBT to TAU in the United Kingdom. If participants with depression and anxiety disorders received relatively effective psychological and/or pharmacological treatments as part of their usual care in these studies, this may account for the smaller difference we observed. For example, one of these studies (Bressi, Porcellana, Marinaccio, Nocito, & Magri, 2010) compared 40 sessions of short-term psychodynamic psychotherapy for depression and anxiety delivered by Psychiatrists over a 12-month period to 12 months of TAU, which consisted of drug treatment combined with "interviews" with a Psychiatrist, which could be scheduled up to four times per month. In this study, it is likely that TAU provided a strong comparison condition. Because there was no independent coding of what the "interviews" entailed, it is even possible that the Psychiatrists in the TAU condition delivered similar psychotherapy to the treatment condition. These findings highlight the need for closer examination of what TAU entails, and highlight the need for future meta-analytic reviews to distinguish studies that use TAU versus WL/no-treatment controls when estimating the value of new treatments (Watts, Turnell, Kladnitski, Newby & Andrews, 2015) .
Another aim of this study was to examine the efficacy of transdiagnostic treatments relative to disorder-specific treatments, in an attempt to clarify the mixed findings in the literature. When compared to the effect sizes found in recent meta-analyses of disorder-specific interventions, the overall effect size difference compared to control conditions is slightly lower than the 0.84 large effect size for reduction in anxiety symptoms across psychological treatments for GAD (Cuijpers et al., 2014) , but higher than average effect sizes for psychological interventions for depression (0.53) (Cuijpers, Andersson, Donker, & Van Straten, 2011) . We found only four studies that directly compared transdiagnostic versus disorder-specific treatments for anxiety and depression, which makes it difficult to draw definitive conclusions about their relative impact. However, our preliminary results suggested that on average, transdiagnostic treatments are at least as efficacious as disorder-specific treatments in reducing anxiety symptoms, and there may be small effects in favour of the transdiagnostic treatments on depression symptoms. Although these results are very preliminary and need to be replicated with a larger number of studies, it suggests that there may be advantages of using a transdiagnostic approach for treating depression symptoms when depression is experienced in the context of comorbid anxiety symptoms. While comparing their differential effects on symptoms is important, future studies also need to compare transdiagnostic and disorder-specific treatments on measures of acceptability to patients and clinicians, their effects on both primary and secondary comorbidities, as well as their costeffectiveness.
We included studies of a range of interventions that adopted the transdiagnostic approach to treatment. Although some studies specifically labelled their intervention as a 'transdiagnostic treatment,' many did not use this terminology. The high level of heterogeneity suggests that there were significant differences in treatment outcomes across these studies, which may be due to critical differences between protocols. Our preliminary findings indicated potential sources of the heterogeneity: both treatment type (CBT versus mindfulness/acceptance) and delivery format (face-to-face individual, face-to-face group, or clinicianguided computerised/internet delivery) influenced outcomes. For example, on average we found that group-based face-to-face transdiagnostic treatments had the smallest (but still moderate to large) effects on anxiety and depression symptoms. Internet-delivered and computerised treatments had the largest effect sizes for depression, and had large effects on anxiety measures, which were similar to the effects found on anxiety measures in individual treatments.
Computerised and internet therapies typically comprise online/ computerised modules or lessons that are delivered over a defined treatment period (e.g., 12 weeks). These text-based lessons/modules teach the patient about depression/anxiety and how to manage their symptoms using practical skills (e.g., graded exposure and thought challenging in CBT). Lessons are typically supplemented with homework exercises to consolidate new learning and encourage skills practice in the patient's daily life, and clinician guidance is often provided via phone or email. Because of their standardised nature, computerised treatments have high treatment fidelity. Since our search was conducted, two additional RCTs have found large and positive effects of transdiagnostic internet CBT for mixed anxiety disorders, providing more evidence in support for their efficacy (Dear, Zou, Ali, et al., 2014; Nordgren et al., 2014) . Future research is critically needed to identify why different treatment effects are observed across delivery formats, and whether it is actually the format of delivery or other aspects of the treatment protocol or participant samples that influence outcomes.
Our results also suggested that, on average, CBT significantly outperformed mindfulness/acceptance-based treatments in reducing anxiety symptoms, but not depression. These results need to be interpreted with caution given that there were relatively few studies of 'third-wave' therapies, and a diverse range of therapies were included in this category. It is possible that CBT was more powerful in reducing anxiety overall because exposure-based techniques are included as a core component in these protocols. Given that the most commonly used measure of anxiety was the BAI, which has been argued to capture symptoms of autonomic arousal rather than other features of anxiety (e.g., worry), it is also possible that CBT is simply more powerful in reducing anxious arousal. This hypothesis is in line with the non-significant but small effects in favour of CBT over MBSR on measures of arousal found by Arch et al. (2013) . Nevertheless, our study highlights the need for more high quality, adequately powered research studies to compare the differential effects of the CBT versus mindfulness-and acceptance-based transdiagnostic treatments on a range of outcome measures (anxiety and depression), and to identify active components that contribute to positive outcomes. Further studies are also needed to explore whether combining conventional or adapted transdiagnostic CBT protocols with mindfulness and/or acceptance-based treatment approaches has any added benefit for the treatment of emotional disorders.
While our results go part way to explaining some of the heterogeneity amongst treatment effects, more research is needed to understand additional sources of heterogeneity. Our review included a diverse set of protocols that included integral (where all patients receive the same fixed protocol), modular and case-formulation driven treatments, as well as tailored interventions that target a patient's primary disorder and comorbid symptoms. The protocols also varied in number and type of anxiety and depressive disorders that were targeted, and the samples varied in terms of severity and comorbidity. It remains unclear which type of transdiagnostic treatment approach is more effective, whether therapist experience influences outcomes, and whether the transdiagnostic treatments are more suitable to specific symptom profiles or diagnostic combinations. In future, it would be helpful to independently review all of the transdiagnostic treatment protocols that have been evaluated to-date, and compare the treatment components/ elements in the protocols that yield the highest effects to those that yield the lowest effects. This may assist in identifying the treatment components that promote positive outcomes for patients, and the most efficacious approach to use when implementing a transdiagnostic protocol.
Limitations
The results of this review need to be interpreted in the context of some limitations. First, due to practical reasons, we only included studies that were published in English; grey literature and unpublished studies were not included in the meta-analysis. Second, our search was restricted to a limited set of databases (PSYCInfo and PubMed). Although we attempted to address this by examining the reference lists of previous meta-analyses and relevant papers, we may have unintentionally omitted articles that met our inclusion criteria because of our restricted search. Third, because we restricted our inclusion criteria to manualised interventions, this is likely to have introduced some bias towards the inclusion of studies of CBT, and exclusion of psychological treatments from other treatment orientations such as psychodynamic psychotherapies (e.g., see Knekt et al., 2008) . Interestingly, evaluation of a unified protocol for the transdiagnostic psychodynamic treatment of anxiety disorders is now underway which will provide a better understanding of the efficacy of psychodynamic treatments that adopt a transdiagnostic treatment approach (Leichsenring & Salzer, 2014) .
Fourth, we only examined the impact of transdiagnostic treatments using self-report measures because clinician-rated instruments were not consistently used across studies, which may have resulted in inflated estimates of effect sizes. Future studies need to examine the impact of these treatments on both clinician-rated and self-reported instruments. Fifth, we did not use a measure of bias risk in the non-randomised studies, although the major methodological limitation of those studies is the absence of a control condition and no randomised estimate of effects. Finally, we used a range of subgroup analyses to explore the possible reasons for the high heterogeneity found in the treatment effects. Because the results from our subgroup analyses are purely observational (Borenstein & Higgins, 2013) , we cannot conclude that treatment type and format caused the differences in outcomes we observed in outcomes. It is also possible that the subgroups differed in other important ways that influenced outcomes (e.g., therapist experience, choice of assessment measure, or quality of study design).
Conclusions
Despite these limitations, the strength of our study is that it is the first to review systematically the comprehensive set of transdiagnostic treatments, across treatment types (e.g., CBT, mindfulness/acceptance and other treatment approaches) and delivery formats (e.g., face-toface individual and group, as well as computerised treatments). Our results provide evidence in support of the efficacy of transdiagnostic treatments in reducing depression and anxiety, and improving quality of life. The quality of RCTs was low overall, and heterogeneity was high. Further high quality RCTs are now needed to explore the sources of this heterogeneity to identify the most effective treatment components and designs, and to understand how transdiagnostic treatments work.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.cpr.2015.06.002.
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